Kirsch Irving
Harvard Medical School, Boston, MA, United States.
Front Psychiatry. 2019 Jun 13;10:407. doi: 10.3389/fpsyt.2019.00407. eCollection 2019.
The aim of this review is to evaluate the placebo effect in the treatment of anxiety and depression. Antidepressants are supposed to work by fixing a chemical imbalance, specifically, a lack of serotonin or norepinephrine in the brain. However, analyses of the published and the unpublished clinical trial data are consistent in showing that most (if not all) of the benefits of antidepressants in the treatment of depression and anxiety are due to the placebo response, and the difference in improvement between drug and placebo is not clinically meaningful and may be due to breaking blind by both patients and clinicians. Although this conclusion has been the subject of intense controversy, the current article indicates that the data from all of the published meta-analyses report the same results. This is also true of recent meta-analysis of all of the antidepressant data submitted to the Food and Drug Administration (FDA) in the process of seeking drug approval. Also, contrary to previously published results, the new FDA analysis reveals that the placebo response has not increased over time. Other treatments (e.g., psychotherapy and physical exercise) produce the same benefits as antidepressants and do so without the side effects and health risks of the active drugs. Psychotherapy and placebo treatments also show a lower relapse rate than that reported for antidepressant medication.
本综述的目的是评估安慰剂效应在焦虑症和抑郁症治疗中的作用。抗抑郁药被认为是通过纠正化学失衡来起作用的,具体而言,是通过补充大脑中缺乏的血清素或去甲肾上腺素。然而,已发表和未发表的临床试验数据分析均一致表明,抗抑郁药在治疗抑郁症和焦虑症方面的大部分(如果不是全部)益处都归因于安慰剂反应,药物与安慰剂之间改善程度的差异在临床上并无意义,且可能是由于患者和临床医生打破盲法所致。尽管这一结论一直是激烈争议的焦点,但本文指出,所有已发表的荟萃分析数据均报告了相同的结果。在寻求药物批准过程中提交给美国食品药品监督管理局(FDA)的所有抗抑郁药数据的近期荟萃分析也是如此。此外,与先前发表的结果相反,FDA的新分析表明,安慰剂反应并未随时间增加。其他治疗方法(如心理治疗和体育锻炼)与抗抑郁药具有相同的疗效,且不会产生活性药物的副作用和健康风险。心理治疗和安慰剂治疗的复发率也低于抗抑郁药物报告的复发率。